<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881215</url>
  </required_header>
  <id_info>
    <org_study_id>AS1811</org_study_id>
    <nct_id>NCT03881215</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma Following Hysteroscopic Adhesolysis</brief_title>
  <official_title>Platelet Rich Plasma Following Hysteroscopic Adhesolysis: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelet Rich Plasma Following Hysteroscopic Adhesolysis: A Randomized Clinical Trial
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adhesion recurrence</measure>
    <time_frame>3 months</time_frame>
    <description>recurrence of severe intra-uterine adhesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of menses</measure>
    <time_frame>3 months</time_frame>
    <description>Number of days of menstrual cycle following operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of menses</measure>
    <time_frame>3 months</time_frame>
    <description>Number of sanitary pads changed during each menstrual cycle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Intra-uterine Adhesions</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-uterine balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet Rich Plasma</intervention_name>
    <description>Platelet Rich Plasma</description>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intra-uterine balloon</intervention_name>
    <description>intra-uterine balloon</description>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <arm_group_label>intra-uterine balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-40 years

          -  Grade III intra-uterine adhesions

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 40 years.

          -  Hb &lt; 11 g/dL, platelets &lt; 150.000/mm3.

          -  Patient taking anticoagulant.

          -  Patient taking NSAID in the 10 days before procedure.

          -  Any significant comorbidity or psychiatric disorder that would compromise patient's
             consent.

          -  Active cervical or uterine infection.

          -  Undiagnosed genital bleeding.

          -  pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>January 26, 2020</last_update_submitted>
  <last_update_submitted_qc>January 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed S Sweed, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

